ML-031 is primarily investigated for its potential therapeutic applications in the field of neuroscience and psychiatry. It acts as a selective agonist for the GPR6 receptor, which is predominantly expressed in the brain, particularly in the striatum. This receptor is implicated in the regulation of motor control and cognitive functions, making ML-031 a candidate for studying and potentially treating neurodegenerative and psychiatric disorders such as Parkinson's disease and schizophrenia. Research focuses on its ability to modulate signaling pathways associated with these conditions, offering insights into novel treatment strategies. Additionally, ML-031 serves as a valuable tool in pharmacological studies to further understand the role of GPR6 in brain function and disease mechanisms.